Loading…
Design Therapeutics, Inc. is projected to rise to $20.78 by 2027, a +37% move from its current price of $15.19. DSGN is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 14 | $14.67 | $15.19 | $15.73 | +0.01% |
| Jul 15 | $14.46 | $15.19 | $15.96 | +0.02% |
| Jul 16 | $14.31 | $15.19 | $16.14 | +0.03% |
| Jul 17 | $14.18 | $15.20 | $16.29 | +0.04% |
| Jul 18 | $14.06 | $15.20 | $16.43 | +0.05% |
| Jul 19 | $13.96 | $15.20 | $16.55 | +0.07% |
| Jul 20 | $13.86 | $15.20 | $16.67 | +0.08% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $13.86 | $15.20 | $16.67 | +0.08% |
| Week 2 | $13.36 | $15.21 | $17.33 | +0.15% |
| Week 3 | $12.98 | $15.22 | $17.86 | +0.23% |
| Week 4 | $12.67 | $15.24 | $18.32 | +0.31% |
| Week 5 | $12.41 | $15.25 | $18.73 | +0.38% |
| Week 6 | $12.18 | $15.26 | $19.12 | +0.46% |
| Week 7 | $11.97 | $15.27 | $19.48 | +0.53% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Design Therapeutics, Inc. is a clinical-stage biopharmaceutical company that researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.
Its lead product candidates for Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function, bringing neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. The company was incorporated in 2017 and is headquartered in Carlsbad, California.
Design Therapeutics, Inc. (DSGN) operates in the Healthcare sector as a clinical-stage biopharmaceutical company focused on genetic diseases using small molecule therapies. The current price is $14.66 and the market capitalization is $915.62M, with a market position reflected by a rank of 2635.
The stock trades within a near-term technical framework that includes a 30-day range and defined support and resistance levels.
A major floor 46.0% below — a decisive break under it would weaken the trend.
The nearest floor, 33.0% below — buyers have tended to step in here.
Price is pressing into resistance (3.0% away) — a breakout level to watch.
A major ceiling 26.0% above — clearing it would confirm fresh momentum.
Key DSGN support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of DSGN market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $15.09 | Buy | $15.11 | Buy |
| MA 10 | $14.78 | Buy | $14.69 | Buy |
| MA 20 | $13.51 | Buy | $13.87 | Buy |
| MA 50 | $12.81 | Buy | $12.89 | Buy |
| MA 100 | $12.00 | Buy | $11.99 | Buy |
| MA 200 | $10.18 | Buy | $10.43 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 65.50 | Neutral |
| Stoch RSI (14) | 27.20 | Neutral |
| CCI (20) | 82.60 | Neutral |
| Williams %R (14) | -19.65 | Info |
| MACD (12,26,9) | 0.18 | Buy |
| ROC (12) | 10.55 | Buy |
| Bollinger %B (20,2) | 0.76 | Neutral |
| Stochastic %K (14) | 80.35 | Sell |
| TRIX (15) | 0.89 | Buy |
| Awesome (5,34) | 2.74 | Buy |
| Ultimate (7,14,28) | 66.69 | Neutral |
| Momentum (10) | 1.75 | Buy |
| Aroon Osc (25) | 80.00 | Buy |
| Hull MA (9) | 15.35 | Sell |
| ADX (14) | 28.67 | Buy |
| ATR (14) | 0.42 | Info |
The near-term sentiment is bullish, with an RSI14 of 70 indicating strength. The stock’s 30-day range runs from $11.51 to $18.68, and it trades above the SMA50 of $12.54 while the SMA200 stands at $9.91. Support is noted at $10.17 and resistance at $14.66, framing a constructive setup in the coming weeks.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $8.69 | $15.19 | $21.71 | 0% | Neutral | |
| $16.12 | $20.78 | $28.57 | +37% | Bullish | |
| $22.09 | $29.54 | $42.50 | +94% | Bullish | |
| $26.79 | $36.94 | $55.05 | +143% | Bullish | |
| $29.42 | $41.68 | $63.97 | +174% | Bullish | |
| $34.83 | $50.58 | $79.65 | +233% | Bullish | |
| $34.34 | $51.05 | $82.25 | +236% | Bullish | |
| $35.76 | $54.34 | $89.38 | +258% | Bullish | |
| $47.77 | $74.15 | $124.28 | +388% | Bullish | |
| $55.92 | $88.57 | $151.07 | +483% | Bullish | |
| $76.40 | $132.88 | $243.77 | +775% | Bullish | |
| $175.18 | $360.22 | $733.76 | +22.7x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $8.69 | $15.19 | $18.75 | +0.00% |
| August 2026 | $13.02 | $15.48 | $18.98 | +1.92% |
| September 2026 | $12.79 | $15.34 | $19.07 | -0.90% |
| October 2026 | $13.45 | $16.26 | $20.45 | +5.96% |
| November 2026 | $13.98 | $17.02 | $21.62 | +4.67% |
| December 2026 | $13.83 | $16.93 | $21.71 | -0.49% |
Click any year to see its month-by-month DSGN forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect DSGN to range from $8.69 to $21.71 through 2026. The $15.19 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The DSGN price prediction for 2027 points to an average of $20.78 (low $16.12, high $28.57) — a potential gain of +37% on today's $15.19. Momentum favours further upside here.
In 2028, DSGN is projected to trade between $22.09 and $42.50, averaging $29.54 — a potential gain of +94% from today's $15.19. That is up +42% on the projected 2027 average. Buyers look set to stay in control over this stretch.
Design Therapeutics, Inc.'s 2029 outlook centres on $36.94, within a $26.79 to $55.05 range. That is up +25% on the projected 2028 average. That marks a +143% change versus current levels. Momentum favours further upside here.
By 2030, DSGN could reach as high as $63.97, with a base case around $41.68 and support toward $29.42 — roughly +174% from $15.19. Buyers look set to stay in control over this stretch.
Expect DSGN to range from $34.83 to $79.65 through 2031. The $50.58 average target implies a +233% move from current prices. That is up +21% on the projected 2030 average. Momentum favours further upside here.
The DSGN price prediction for 2032 points to an average of $51.05 (low $34.34, high $82.25) — a potential gain of +236% on today's $15.19. Buyers look set to stay in control over this stretch.
In 2033, DSGN is projected to trade between $35.76 and $89.38, averaging $54.34 — a potential gain of +258% from today's $15.19. That is up +6% on the projected 2032 average. Momentum favours further upside here.
Design Therapeutics, Inc.'s 2034 outlook centres on $74.15, within a $47.77 to $124.28 range. That is up +36% on the projected 2033 average. That marks a +388% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, DSGN could reach as high as $151.07, with a base case around $88.57 and support toward $55.92 — roughly +483% from $15.19. Momentum favours further upside here.
Expect DSGN to range from $76.40 to $243.77 through 2040. The $132.88 average target implies a +775% move from current prices. That is up +50% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The DSGN price prediction for 2050 points to an average of $360.22 (low $175.18, high $733.76) — a potential gain of +22.7x on today's $15.19. Momentum favours further upside here.
Investing $1,000 in DSGN today (≈ 65.832785 DSGN) could be worth
$23,713.99
+$22,713.99 (+2271%) by 2050 · US Dollar
Based on the average projected DSGN price of $360.22 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in DSGNwould be worth at today's price.
$1,000 invested in DSGN on Jul 10, 2025 (≈ 247.524755 DSGN) would be worth
$3,759.9
+$2,759.9 (+276.0%) today · 3.76× · US Dollar
Based on a DSGN entry price of $4.04 vs. today's $15.19.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $15.64 | $971.23 | -2.9% |
| 1 month ago | $10.66 | $1,424.95 | +42.5% |
| 3 months ago | $12.16 | $1,249.18 | +24.9% |
| 6 months ago | $9.12 | $1,665.57 | +66.6% |
| 1 year ago | $4.04 | $3,759.9 | +276.0% |
| All time (5.0y) ago | $17.35 | $875.5 | -12.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our DSGN forecast.
Our base-case forecast reaches $30.00 around 2029.
Implied market cap at $30.00: $1.87B
The multi-year forecast envisions a bullish trajectory with rising average prices across the years. The 2026 average is $14.66 with a 0% ROI and neutral sentiment, followed by strong upside thereafter: 2027 average $20.49 (ROI 39.8%, bullish), 2028 average $28.56 (ROI 94.8%, bullish), 2029 average $36.08 (ROI 146.1%, bullish), 2030 average $41.43 (ROI 182.6%, bullish), 2031 average $48.98 (ROI 234.1%, bullish), 2032 average $49.10 (ROI 235%, bullish), 2033 average $53.32 (ROI 263.7%, bullish), 2034 average $72.29 (ROI 393.1%, bullish), 2035 average $86.32 (ROI 488.8%, bullish), 2040 average $127.87 (ROI 772.3%, bullish), and 2050 average $353.02 (ROI 2308.1%, bullish). The forecasted path suggests substantial upside over the long term, but these figures are estimates and not guarantees, with near-term uncertainty and risk remaining.
Tap a question to reveal the answer.
The forecast shows an average price of $41.43, with a minimum of $28.84 and a maximum of $64.51, and a projected ROI of 182.6% with bullish sentiment.
The long-term forecast is bullish in many years, with the average price rising from $14.66 in 2026 to $41.43 by 2030 and higher by 2050. Projected ROIs reach 182.6% in 2030 and 2308.1% by 2050, though 2026 is neutral with a 0% ROI; these are estimates, not guarantees.
Yes. The forecasted maximum prices exceed $100 in several years: $123.33 in 2034 and $149.96 in 2035, with even higher maxima in later years (e.g., $239.53 in 2040 and $736.76 in 2050). These figures are estimates and not guarantees.
Current price is $14.66 and the market capitalization is $915.62M.
The annualized volatility is 70%, indicating relatively high price fluctuation potential.
Design Therapeutics, Inc. Community Discussion
0Share your Design Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.